Última actualización 24 de agosto de 2026
Key finding
TG levels decreased by -0.56 mmol/L (95% CI: -0.71, -0.42) in the PEG-Loxe group.
This study compared the efficacy and safety of polyethylene glycol loxenatide (PEG-Loxe) and dapagliflozin in patients with mild-to-moderate diabetic kidney disease, finding both treatments effective in reducing urinary albumin-to-creatinine ratio.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Risk of bias
Some Concerns
Guarda investigacion, organiza estudios y vuelve a encontrar evidencia importante rapidamente.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
This study compared the efficacy and safety of polyethylene glycol loxenatide (PEG-Loxe) and dapagliflozin in patients with mild-to-moderate diabetic kidney disease, finding both treatments effective in reducing urinary albumin-to-creatinine ratio.
This research is significant as it provides evidence supporting the use of PEG-Loxe as a potential treatment option for patients with diabetic kidney disease, a condition that complicates diabetes management. Understanding the efficacy of these medications can help clinicians make informed treatment decisions to improve patient outcomes.
The study did not report significant differences in blood pressure between groups. The sample size and demographic characteristics may limit generalizability. Effectiveness claims were unclear for some outcomes.
Published in
Publication details and source links for this paper.
YongSheng C, Shujie C, Jiangang Z, Jianqin Z, Yanan Z, Ying L. Efficacy and Safety of Polyethylene Glycol Loxenatide Compared to Dapagliflozin in Patients with Mild-to-Moderate Diabetic Kidney Disease. Frontiers in Endocrinology. 2024;15:1387993. doi:10.3389/fendo.2024.1387993
PEG-Loxe group showed a mean percent change in UACR of -29.3% (95% CI: -34.8, -23.7).
Dapagliflozin group exhibited a mean percent change in UACR of -31.8% (95% CI: -34.8, -23.7).
HbA1c levels decreased by -1.30% (95% CI: -1.43, -1.18) in the PEG-Loxe group.
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Dapagliflozin, PEG-Loxe 300 µg/week and Diastolic blood pressure, HbA1c, Systolic blood pressure, and 2 more.
This study contributes evidence to
Primary intervention
Dapagliflozin
Primary outcomes
Evidence topics
Primary intervention
Primary outcomes
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
3
Related topics
10
Evidence pairs
561
Related studies
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.
Evidencia principal
Relación de evidencia
Evidencia relacionada
Relación de evidencia
Guardar evidencia
Relación de evidencia
Guardar evidencia
Core evidence
The primary outcomes reported in this study.
Dapagliflozin → Diastolic blood pressure
Dapagliflozin → Diastolic blood pressure
Dapagliflozin → Systolic blood pressure
Dapagliflozin → Systolic blood pressure
Dapagliflozin → Urinary albumin-to-creatinine ratio
Dapagliflozin → Urinary albumin-to-creatinine ratio
PEG-Loxe 300 µg/week → Diastolic blood pressure
PEG-Loxe 300 µg/week → Diastolic blood pressure
PEG-Loxe 300 µg/week → Systolic blood pressure
PEG-Loxe 300 µg/week → Systolic blood pressure
PEG-Loxe 300 µg/week → Urinary albumin-to-creatinine ratio
PEG-Loxe 300 µg/week → Urinary albumin-to-creatinine ratio
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on SGLT2 Inhibitors and HbA1c, SGLT2 Inhibitors and Blood Pressure.
This study contributes to the evidence on the following intervention-outcome relationships.
Medications
Medications
Curated evidence collections and hubs this study is part of.
All studies measuring HbA1c
Measures HbA1c as a key outcome.
All studies on SGLT2 Inhibitors
Contributes to SGLT2 Inhibitors evidence base.
All studies measuring Blood Pressure
Measures Blood Pressure as a key outcome.
Latest published studies
Published within the last 2 years.
Jump to pre-filtered views in Evidence Explorer.
7 results
4 results
7 results
7 results
4 results
Generated from the study's connected evidence using Evidence Intelligence™.
SGLT2 Inhibitors may improve HbA1c.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
HbA1c
EvidenceScore™ Strong | EvidenceScore™ 79.4 | moderate positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 19 supporting studies with consistent results and a positive effect signal.
Limitations
SGLT2 Inhibitors may improve Kidney Function.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
Urinary albumin-to-creatinine ratio
EvidenceScore™ Moderate | EvidenceScore™ 74.6 | moderate positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 10 supporting studies with consistent results and a positive effect signal.
Limitations
SGLT2 Inhibitors may improve Adipokine and Angiogenic Markers.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
Triglycerides
EvidenceScore™ Moderate | EvidenceScore™ 71.5 | strong positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 9 supporting studies with consistent results and a positive effect signal.
Limitations
SGLT2 Inhibitors may improve Blood Pressure.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
Systolic blood pressure
EvidenceScore™ Moderate | EvidenceScore™ 74.6 | moderate positive | ConsistencyScore™ Consistent | 1 study
Diastolic blood pressure
EvidenceScore™ Moderate | EvidenceScore™ 63.1 | neutral | ConsistencyScore™ Mixed | 1 study
Why this answer: This answer is based on 6 supporting studies with consistent results and a positive effect signal.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Follow the topics this study contributes to.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Centrada en la evidencia, no en la publicidad.
Tus datos siempre están protegidos.
Se agregan nuevos estudios todos los días.
